menu
    • menu
    [{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate||Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The Royal Wolverhampton Hospitals NHS Trust","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Oncology","graph2":"Phase III","graph3":"The Royal Wolverhampton Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Royal Wolverhampton Hospitals NHS Trust \/ Norgine","highestDevelopmentStatusID":"10","companyTruncated":"The Royal Wolverhampton Hospitals NHS Trust \/ Norgine"},{"orgOrder":0,"company":"Hannover Medical School","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hannover Medical School","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hannover Medical School \/ Norgine","highestDevelopmentStatusID":"11","companyTruncated":"Hannover Medical School \/ Norgine"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Shield Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Nephrology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Ferric Maltol

    Menu

    Ferric Maltol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hannover Medical School

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hannover Medical School

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Fa...

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 25, 2023

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Royal Wolverhampton Hospitals NHS Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            The Royal Wolverhampton Hospitals NHS Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Perioperative Iron for Colorectal Cancer (PICoC Study)

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colonic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 04, 2022

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children ...

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            November 19, 2021

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Australia’s Therapeutic Goods Administration (TGA) Approves Feraccru® to Treat Iron Deficiency With or With...

                            Details : The commercial stage pharmaceutical company focused on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol) confirmed to investors that the TGA has registered Feraccru® as a treatment in the Australian Register of Thera...

                            Product Name : Feraccru

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 09, 2021

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            November 12, 2020

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Beijing Aosaikang Pharmaceutical

                            Deal Size : $62.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            China licence agreement for Feraccru/Accrufer

                            Details : Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .

                            Product Name : Feraccru

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : $11.4 million

                            January 08, 2020

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Beijing Aosaikang Pharmaceutical

                            Deal Size : $62.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Def...

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 08, 2017

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Dise...

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            November 18, 2016

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia ...

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 11, 2016

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shield Therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (A...

                            Details : Ferric Maltol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            May 11, 2011

                            Lead Product(s) : Ferric Maltol

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth